Should I buy or sell Abeona Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABEO shares. View ABEO analyst ratings or view top-rated stocks .

What is Abeona Therapeutics' stock price target for 2024?

1 brokerages have issued twelve-month target prices for Abeona Therapeutics' shares. Their ABEO share price targets range from $38.00 to $38.00. On average, they predict the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 402.0% from the stock's current price. View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts .

How have ABEO shares performed in 2024?

Abeona Therapeutics' stock was trading at $5.01 at the beginning of the year. Since then, ABEO shares have increased by 51.1% and is now trading at $7.57. View the best growth stocks for 2024 here .

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,990,000 shares, an increase of 17.1% from the March 15th total of 1,700,000 shares. Based on an average trading volume of 333,800 shares, the days-to-cover ratio is presently 6.0 days. Approximately 7.7% of the shares of the company are sold short. View Abeona Therapeutics' Short Interest .

When is Abeona Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ABEO earnings forecast .

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) issued its earnings results on Monday, March, 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.

When did Abeona Therapeutics' stock split?

Abeona Therapeutics's stock reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Abeona Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI) , Corbus Pharmaceuticals (CRBP) , OPKO Health (OPK) , Sangamo Therapeutics (SGMO) , Energy Transfer (ET) , Sorrento Therapeutics (SRNE) , Micron Technology (MU) , TherapeuticsMD (TXMD) , VBI Vaccines (VBIV) and Advanced Micro Devices (AMD) .

How do I buy shares of Abeona Therapeutics?

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABEO

Abeona Therapeutics (ABEO) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free ABEO Stock Alerts

$7.57

+0.04 (+0.53%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.20
▼
$7.69
50-Day Range: $6.15
▼
$8.68
52-Week Range: $2.83
▼
$9.01

Volume: 386,264 shs
Average Volume: 325,152 shs
Market Capitalization: $207.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.00

Get Abeona Therapeutics alerts:

Abeona Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 402.0% Upside
$38.00 Price Target
Short Interest: Bearish
7.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.03
Upright™ Environmental Score
News Sentiment: 0.85
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.83) to ($1.55) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.76 out of 5 stars

Medical Sector

220th out of 911 stocks

Pharmaceutical Preparations Industry

85th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Abeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Abeona Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.73% of the float of Abeona Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Abeona Therapeutics has a short interest ratio ("days to cover") of 6.
Change versus previous month
Short interest in Abeona Therapeutics has recently increased by 17.06%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Abeona Therapeutics does not currently pay a dividend.
Dividend Growth
Abeona Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Abeona Therapeutics has received a 69.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Abeona Therapeutics is -1.03.

2.7

News and Social Media Coverage

News Sentiment
Abeona Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 12 people have searched for ABEO on MarketBeat in the last 30 days. This is a decrease of -37% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Abeona Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.30% of the stock of Abeona Therapeutics is held by insiders.
Percentage Held by Institutions
80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Abeona Therapeutics are expected to grow in the coming year, from ($1.83) to ($1.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Abeona Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Abeona Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Abeona Therapeutics has a P/B Ratio of 12.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Abeona Therapeutics Stock (NASDAQ:ABEO)

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

ABEO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABEO Stock News Headlines

April 16, 2024 | americanbankingnews.com

Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com

April 14, 2024 | americanbankingnews.com

Abeona Therapeutics Inc (NASDAQ:ABEO) Short Interest Update

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 1, 2024 | globenewswire.com

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2024 | finance.yahoo.com

Here's Why We're Not Too Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

March 19, 2024 | investorplace.com

ABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023

March 19, 2024 | finance.yahoo.com

Q4 2023 Abeona Therapeutics Inc Earnings Call

March 19, 2024 | finance.yahoo.com

Abeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial Results

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 18, 2024 | msn.com

Inventiva Phase 2 study for MASH drug meets primary endpoint

March 18, 2024 | marketwatch.com

Abeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland Facility

March 18, 2024 | finanznachrichten.de

Abeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

March 18, 2024 | msn.com

Abeona Therapeutics GAAP EPS of -$2.53, revenue of $3.5M

March 18, 2024 | globenewswire.com

Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections

March 16, 2024 | finance.yahoo.com

ABEO Dec 2024 15.000 call

March 10, 2024 | fool.com

Abeona Therapeutics (NASDAQ: ABEO)

March 10, 2024 | finance.yahoo.com

Several Insiders Invested In Abeona Therapeutics Flagging Positive News

March 5, 2024 | globenewswire.com

Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 22, 2024 | benzinga.com

Abeona Therapeutics Stock (NASDAQ:ABEO), Short Interest Report

February 21, 2024 | benzinga.com

Abeona Therapeutics Stock (NASDAQ:ABEO) Insider Trades

February 20, 2024 | money.usnews.com

Abeona Therapeutics Inc

February 19, 2024 | finance.yahoo.com

ABEO Apr 2024 7.500 call

February 16, 2024 | finance.yahoo.com

ABEO Mar 2024 10.000 call

February 16, 2024 | investing.com

Abeona Therapeutics Inc (ABEO)

February 15, 2024 | finance.yahoo.com

Steven Cohen's Firm Increases Stake in Abeona Therapeutics Inc

February 12, 2024 | finance.yahoo.com

Individual investors in Abeona Therapeutics Inc. (NASDAQ:ABEO) are its biggest bettors, and their bets paid off as stock gained 45% last week

February 3, 2024 | finanznachrichten.de

Abeona Therapeutics Inc.: Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)

See More Headlines

Receive ABEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/18/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ABEO
Previous Symbol: OTCMKTS:ACCP
CUSIP: N/A
CIK: 318306
Web: www.abeonatherapeutics.com
Phone: 214-665-9495
Fax: 214-905-5101
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $38.00
High Stock Price Target: $38.00
Low Stock Price Target: $38.00
Potential Upside/Downside: +404.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,190,000.00
Net Margins: N/A
Pretax Margin: -1,548.23%
Return on Equity: -280.58%
Return on Assets: -76.90%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.15
Quick Ratio: 4.15

Sales & Book Value

Annual Sales: $3.50 million
Price / Sales: 58.84
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.60 per share
Price / Book: 12.55

Miscellaneous

Outstanding Shares: 27,350,000
Free Float: 25,905,000
Market Cap: $205.95 million
Optionable: Optionable
Beta: 1.49

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Steven H. Rouhandeh (Age 61)
Exec. Chairman
Dr. Timothy J. Miller (Age 46)
Pres, Chief Scientific Officer & Director
Mr. Jeffrey Blaine Davis (Age 55)
Chief Operating Officer
Mr. Carsten Thiel (Age 54)
Chief Exec. Officer
Mr. Stephen B. Thompson (Age 64)
Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABEO Stock Analysis - Frequently Asked Questions

Should I buy or sell Abeona Therapeutics stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings or view top-rated stocks.
What is Abeona Therapeutics' stock price target for 2024?: 1 brokerages have issued twelve-month target prices for Abeona Therapeutics' shares. Their ABEO share price targets range from $38.00 to $38.00. On average, they predict the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 402.0% from the stock's current price.
View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts.
How have ABEO shares performed in 2024?: Abeona Therapeutics' stock was trading at $5.01 at the beginning of the year. Since then, ABEO shares have increased by 51.1% and is now trading at $7.57.
View the best growth stocks for 2024 here.
Are investors shorting Abeona Therapeutics?: Abeona Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,990,000 shares, an increase of 17.1% from the March 15th total of 1,700,000 shares. Based on an average trading volume of 333,800 shares, the days-to-cover ratio is presently 6.0 days. Approximately 7.7% of the shares of the company are sold short.
View Abeona Therapeutics' Short Interest.
When is Abeona Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ABEO earnings forecast.

How were Abeona Therapeutics' earnings last quarter?: Abeona Therapeutics Inc (NASDAQ:ABEO) issued its earnings results on Monday, March, 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.
When did Abeona Therapeutics' stock split?: Abeona Therapeutics's stock reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What other stocks do shareholders of Abeona Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).
How do I buy shares of Abeona Therapeutics?: Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABEO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial